Article

Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice.

Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen DK-2200, Denmark.
The Journal of Immunology (impact factor: 5.79). 02/2011; 186(7):3997-4007. DOI:10.4049/jimmunol.1001251 pp.3997-4007
Source: PubMed

ABSTRACT The impact of prophylactic vaccination against acute and chronic infection in a Th-deficient host has not been adequately addressed because of difficulties in generating protective immunity in the absence of CD4(+) T cell help. In this study, we demonstrated that a broad CD8(+) T cell immune response could be elicited in MHC class II-deficient mice by vaccination with adenovirus encoding lymphocytic choriomeningitis virus (LCMV) glycoprotein tethered to MHC class II-associated invariant chain. Moreover, the response induced conferred significant cytolytic CD8(+) T cell-mediated protection against challenge with a high dose of the invasive clone 13 strain of LCMV. In contrast, vaccination with adenovirus encoding unlinked LCMV glycoprotein induced weak virus control in the absence of CD4(+) T cells, and mice may die of increased immunopathology associated with incomplete protection. Acute mortality was not observed in any vaccinated mice following infection with the less-invasive Traub strain. However, LCMV Traub infection caused accelerated late mortality in unvaccinated MHC class II-deficient mice; in this case, we observed a strong trend toward delayed mortality in vaccinated mice, irrespective of the nature of the vaccine. These results indicated that optimized vaccination may lead to efficient protection against acute viral infection, even in Th-deficient individuals, but that the duration of such immunity is limited. Nevertheless, for select immunodeficiencies in which CD4(+) T cell deficiency is incomplete or transient, these results are very encouraging.

0 0
 · 
0 Bookmarks
 · 
29 Views
  • Article: Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses.
    [show abstract] [hide abstract]
    ABSTRACT: Adenoviral vectors have shown a great potential for vaccine development due to their inherent ability to induce potent and protective CD8 T-cell responses. However, a critical issue regarding the use of these vectors is the existence of inhibitory immunity against the most commonly used Ad5 vector in a large part of the human population. We have recently developed an improved adenoviral vaccine vector system in which the vector expresses the transgene tethered to the MHC class II associated invariant chain (Ii). To further evaluate the potential of this system, the concept of pre-existing inhibitory immunity to adenoviral vectors was revisited to investigate whether the inhibition previously seen with the Ad5 vector also applied to the optimized vector system. We found this to be the case, and antibodies dominated as the mechanism underlying inhibitory vector immunity. However, presence of CD8 T cells directed against epitopes in the adenoviral vector seemed to correlate with repression of the induced response in re-vaccinated B-cell deficient mice. More importantly, despite a repressed primary effector CD8 T-cell response in Ad5-immune animals subjected to vaccination, memory T cells were generated that provided the foundation for an efficient recall response and protection upon subsequent viral challenge. Furthermore, the transgene specific response could be efficiently boosted by homologous re-immunization. Taken together, these studies indicate that adenoviral vectors can be used to induce efficient CD8 T-cell memory even in individuals with pre-existing vector immunity.
    PLoS ONE 01/2012; 7(4):e34884. · 4.09 Impact Factor

Keywords

Acute mortality
 
adenovirus encoding lymphocytic choriomeningitis virus
 
adenovirus encoding unlinked LCMV glycoprotein induced weak virus control
 
chronic infection
 
efficient protection
 
incomplete protection
 
invasive clone 13 strain
 
LCMV Traub infection
 
less-invasive Traub strain
 
MHC class II-associated invariant chain
 
MHC class II-deficient mice
 
optimized vaccination
 
prophylactic vaccination
 
protective immunity
 
response induced
 
significant cytolytic CD8(+)
 
strong trend
 
unvaccinated MHC class II-deficient mice
 
vaccination
 
vaccine